Aclaris Therapeutics, Inc. — Director's Dealing 2016

Oct 28, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aclaris Therapeutics, Inc. (ACRS)
CIK: 0001557746
Period of Report: 2016-10-26

Reporting Person: FMR LLC (10% Owner, See Remark 1)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-10-26	Common Stock	S	3650	$21.93	Disposed	2571454	Indirect
2016-10-26	Common Stock	S	100	$22.15	Disposed	2571354	Indirect

Footnotes

F1: By F-Prime Capital Partners Healthcare Fund III LP (456,514 shares of Common Stock), F-Prime Capital Partners Healthcare Advisors Fund III LP (8,765 shares of Common Stock), Impresa Fund III Limited Partnership (2,103,015 shares of Common Stock) and F-Prime Inc (3,060 shares of Common Stock). The general partner of F-Prime Capital Partners Healthcare Fund III LP is F-Prime Capital Partners Healthcare Advisors Fund III LP (FPCPHA). FPCPHA and Impresa Fund III Limited Partnership are each solely managed by Impresa Management LLC, their general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. F-Prime Inc. is a wholly-owned subsidiary of FMR LLC.

F2: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $21.86 to $22.19. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.